Compile Data Set for Download or QSAR
maximum 50k data
Found 56 Enz. Inhib. hit(s) with all data for entry = 9140
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141416(US10668051, Compound Example 67 | US8921364, 67)
Affinity DataIC50:  20.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141426(US10668051, Compound Example 84 | US8921364, 84)
Affinity DataIC50:  20.8nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141438(US10668051, Compound Example 104 | US8921364, 104)
Affinity DataIC50:  23nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141428(US10668051, Compound Example 87 | US8921364, 87)
Affinity DataIC50:  32.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141421(US10668051, Compound Example 78 | US8921364, 78)
Affinity DataIC50:  34.1nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141424(US10668051, Compound Example 82 | US8921364, 82)
Affinity DataIC50:  35.7nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141396(US10668051, Compound Example 7 | US8921364, 7)
Affinity DataIC50:  36.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141444(US10668051, Compound Example 114 | US8921364, 114)
Affinity DataIC50:  37.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141442(US10668051, Compound Example 111 | US8921364, 111)
Affinity DataIC50:  47.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141419(US10668051, Compound Example 74 | US8921364, 74)
Affinity DataIC50:  48nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141418(US10668051, Compound Example 72 | US8921364, 72)
Affinity DataIC50:  48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141425(US10668051, Compound Example 83 | US8921364, 83)
Affinity DataIC50:  48.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141441(US10668051, Compound Example 108 | US8921364, 108)
Affinity DataIC50:  50.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141448(US10668051, Compound Example 126 | US8921364, 126)
Affinity DataIC50:  52.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141439(US10668051, Compound Example 106 | US8921364, 106)
Affinity DataIC50:  60nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141402(US10668051, Compound Example 28 | US8921364, 28)
Affinity DataIC50:  60.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141393(US10668051, Compound Example 1 | US8921364, 1)
Affinity DataIC50:  62.4nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141443(US10668051, Compound Example 113 | US8921364, 113)
Affinity DataIC50:  62.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141412(US10668051, Compound Example 56 | US8921364, 56)
Affinity DataIC50:  63.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141409(US10668051, Compound Example 49 | US8921364, 49)
Affinity DataIC50:  65.5nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141440(US10668051, Compound Example 107 | US8921364, 107)
Affinity DataIC50:  70.3nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141411(US10668051, Compound Example 53 | US8921364, 53)
Affinity DataIC50:  72nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141445(US10668051, Compound Example 122 | US8921364, 122)
Affinity DataIC50:  72.1nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141434(US10668051, Compound Example 93 | US8921364, 93)
Affinity DataIC50:  81.2nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141429(US10668051, Compound Example 88 | US8921364, 88)
Affinity DataIC50:  98.6nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141436(US10668051, Compound Example 100 | US8921364, 100)
Affinity DataIC50:  99.7nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141414(US10668051, Compound Example 60 | US8921364, 60)
Affinity DataIC50:  120nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141413(US10668051, Compound Example 57 | US8921364, 57)
Affinity DataIC50:  124nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141422(US10668051, Compound Example 79 | US8921364, 79)
Affinity DataIC50:  124nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141399(US10668051, Compound Example 17 | US8921364, 17)
Affinity DataIC50:  130nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141397(US10668051, Compound Example 15 | US8921364, 15)
Affinity DataIC50:  141nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141403(US10668051, Compound Example 33 | US8921364, 33)
Affinity DataIC50:  145nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141427(US10668051, Compound Example 86 | US8921364, 86)
Affinity DataIC50:  147nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141437(US10668051, Compound Example 101 | US8921364, 101)
Affinity DataIC50:  150nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141433(US10668051, Compound Example 92 | US8921364, 92)
Affinity DataIC50:  159nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141432(US10668051, Compound Example 91 | US8921364, 91)
Affinity DataIC50:  159nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141406(US10668051, Compound Example 37 | US8921364, 37)
Affinity DataIC50:  181nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141410(US10668051, Compound Example 52 | US8921364, 52)
Affinity DataIC50:  184nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141404(US10668051, Compound Example 35 | US8921364, 35)
Affinity DataIC50:  185nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141423(US10668051, Compound Example 80 | US8921364, 80)
Affinity DataIC50:  194nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141430(US10668051, Compound Example 89 | US8921364, 89)
Affinity DataIC50:  206nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141394(US10668051, Compound Example 2 | US8921364, 2)
Affinity DataIC50:  207nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141405(US10668051, Compound Example 36 | US8921364, 36)
Affinity DataIC50:  224nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141431(US10668051, Compound Example 90 | US8921364, 90)
Affinity DataIC50:  232nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141398(US10668051, Compound Example 16 | US8921364, 16)
Affinity DataIC50:  244nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141415(US10668051, Compound Example 66 | US8921364, 66)
Affinity DataIC50:  255nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141395(US10668051, Compound Example 4 | US8921364, 4)
Affinity DataIC50:  256nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141420(US10668051, Compound Example 76 | US8921364, 76)
Affinity DataIC50:  269nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141446(US10668051, Compound Example 124 | US8921364, 124)
Affinity DataIC50:  295nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCalcium release-activated calcium channel protein 1(Homo sapiens (Human))
Rhizen Pharmaceuticals

US Patent
LigandPNGBDBM141447(US10668051, Compound Example 125 | US8921364, 125)
Affinity DataIC50:  373nMAssay Description:Inhibition of CRAC channels was determined following thapsigargin (Sigma, Cat #T9033) induced endoplasmic calcium release in Jurkat cells, (see Yasur...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: